Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Metabolic Disorders

Set Alert for Metabolic Disorders

Travere Looks Ahead To Phase III In Homocystinuria

The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.

Clinical Trials Rare Diseases

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.

Clinical Trials Commercial

Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments

Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.

Research & Development Strategy

Novo’s Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III

A 50mg dose of oral semaglutide showed similar weight loss to the weekly injectable version that Novo already markets as Wegovy.

Metabolic Disorders Research & Development

Novo Nordisk’s Obesity Drug Activities Break UK Rules Again

The company has been found in breach of the UK code once again for its work with pharmacists,  although this time Novo Nordisk has escaped the heaviest censure.

Companies Commercial

Cystinosis Results Help Rebuild Confidence In AvroBio’s Gene Therapy

The lentiviral gene therapy company is still trading below cash, but the cystinosis results add extra momentum to its comeback.

Metabolic Disorders Commercial

Poxel Looks To More Twymeeg Partnerships In Asia To Pay Off Debt

The French firm’s antidiabetic drug has enjoyed some traction in the Japanese market following the end of launch year restrictions, raising hopes that other Asian partnerships could help improve its financial position.

Sales & Earnings Deals

Belgium's Sequana Sits At Junction Between Pharma And Medtech

The company’s dual drug-device development pipeline is progressing well, especially its direct sodium removal therapy for congestive heart failure.

Cardiovascular Business Strategies

Boehringer/Zealand’s Obesity Asset Succeeds In Phase II But Competition Is Fierce

The partners’ dual GLP-1/GCGR agonist has achieved up to 14.9% weight loss in obese and overweight adults in a mid-stage trial but rival products Wegovy and Mounjaro will likely dominate the space according to analysts.

Clinical Trials Metabolic Disorders

Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity

Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.

Metabolic Disorders Sales & Earnings

Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market

Excluding COVID-19 antibodies, the company said revenues for the quarter increased by 10% while volume increased by 18%, and sales of Mounjaro came in stronger than analysts anticipated.

Sales & Earnings Metabolic Disorders

Sanofi Sees Dupixent As Just The Start Of COPD Transformation

Dupixent’s surprise success in COPD is welcome news, but it remains uncertain whether regulators will demand a second study readout before filing. In the meantime, Sanofi highlighted another promising late-stage candidate for the hard-to-treat disease during its Q1 results.

Sales & Earnings Clinical Trials
See All
UsernamePublicRestriction

Register